The patent on Revlimid expires in January 2026 and the three pharma majors, which have seen strong growth on the back of this drug, are looking for other opportunities to keep their growth path. They appear to have aces up their sleeves.
Even though the company’s profit, revenue and profitability exceeded expectations, brokerages feel that the growth in recent quarters was fuelled by the spectacular sales of Revlimid. They say the contribution from the drug will soon start waning out, and many still retain their ‘hold’ and ‘sell’ calls.
It’s not as if domestic manufacturing has suddenly become sloppy. A closer look will reveal the strides made by Indian pharma firms as they attempt to break into the complex drugs space, which attracts higher scrutiny.